Adrafinil vs Phenibut

Mechanism

Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).

Standard Dosing

300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)

Timing

Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.

Cycle Duration

Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.

Side Effects

• All modafinil side effects apply
• Elevated liver enzymes (ALT/AST)
• Potential hepatotoxicity with chronic use
• Skin reactions
• GI distress (more common than with modafinil due to hepatic metabolism)

Contraindications

• Hepatic impairment of any severity
• Concurrent hepatotoxic medication
• All contraindications for modafinil apply (cardiac conditions, anxiety disorders, pregnancy)
• History of liver disease or elevated liver enzymes

Best Stacking Partners

Mechanism

Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.

Standard Dosing

250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)

Timing

On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.

Cycle Duration

STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.

Side Effects

• Drowsiness/sedation
• Dizziness
• Nausea
• Tolerance (develops rapidly)
• Physical dependence (can occur within 1-2 weeks of daily use)
• Withdrawal syndrome (anxiety, insomnia, tremor, psychosis, hallucinations, seizures)
• Hangover effect
• Motor incoordination at high doses

Contraindications

• History of substance use disorder
• Epilepsy
• Renal impairment (primarily renally excreted)
• Concurrent use of any CNS depressant
• Pregnancy and lactation
• Severe hepatic impairment
• History of benzodiazepine or alcohol dependence

Best Stacking Partners